4.6 Article

Regional distribution and maturation of tau pathology among phenotypic variants of Alzheimer's disease

Journal

ACTA NEUROPATHOLOGICA
Volume 144, Issue 6, Pages 1103-1116

Publisher

SPRINGER
DOI: 10.1007/s00401-022-02472-x

Keywords

Alzheimer's disease; Neurofibrillary tangles; Tau; Non-amnestic AD

Funding

  1. NIH [NINDS R01-NS109260-01A1, NIA P01-AG066597, NIA P30-AG072979]
  2. NIA [R01-AG054519-02]
  3. Penn Institute on Aging
  4. Brightfocus Foundation [A2016244S]
  5. Alzheimer's Association [AARF-D-619473, AARF-D-619473-RAPID]
  6. Wyncote Foundation

Ask authors/readers for more resources

Alzheimer's disease can present with different clinical variants due to heterogeneous neuropathologic changes. This study investigated the distribution and burden of tau pathologies in different brain regions among amnestic and non-amnestic phenotypic variants of Alzheimer's disease. The results showed that there were differences in the distribution and burden of tau pathologies between the two groups, suggesting that the neuronal susceptibility to tau-mediated neurodegeneration may influence the clinical expression of Alzheimer's disease.
Alzheimer's disease neuropathologic change (ADNC) is clinically heterogenous and can present with a classic multidomain amnestic syndrome or focal non-amnestic syndromes. Here, we investigated the distribution and burden of phosphorylated and C-terminally cleaved tau pathologies across hippocampal subfields and cortical regions among phenotypic variants of Alzheimer's disease (AD). In this study, autopsy-confirmed patients with ADNC, were classified into amnestic (aAD, N = 40) and non-amnestic (naAD, N = 39) groups based on clinical criteria. We performed digital assessment of tissue sections immunostained for phosphorylated-tau (AT8 detects pretangles and mature tangles), D-421-truncated tau (TauC3, a marker for mature tangles and ghost tangles), and E-391-truncated tau (MN423, a marker that primarily detects ghost tangles), in hippocampal subfields and three cortical regions. Linear mixed-effect models were used to test regional and group differences while adjusting for demographics. Both groups showed AT8-reactivity across hippocampal subfields that mirrored traditional Braak staging with higher burden of phosphorylated-tau in subregions implicated as affected early in Braak staging. The burden of phosphorylated-tau and TauC3-immunoreactive tau in the hippocampus was largely similar between the aAD and naAD groups. In contrast, the naAD group had lower relative distribution of MN423-reactive tangles in CA1 (beta = - 0.2, SE = 0.09, p = 0.001) and CA2 (beta = - 0.25, SE = 0.09, p = 0.005) compared to the aAD. While the two groups had similar levels of phosphorylated-tau pathology in cortical regions, there was higher burden of TauC3 reactivity in sup/mid temporal cortex (beta = 0.16, SE = 0.07, p = 0.02) and MN423 reactivity in all cortical regions (beta = 0.4-0.43, SE = 0.09, p < 0.001) in the naAD compared to aAD. In conclusion, AD clinical variants may have a signature distribution of overall phosphorylated-tau pathology within the hippocampus reflecting traditional Braak staging; however, non-amnestic AD has greater relative mature tangle pathology in the neocortex compared to patients with clinical amnestic AD, where the hippocampus had greatest relative burden of C-terminally cleaved tau reactivity. Thus, varying neuronal susceptibility to tau-mediated neurodegeneration may influence the clinical expression of ADNC.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available